Hanis, Phyu Nitar, Hakim, Wong FY, Kusumawidjaja G, RX Wong

Association of blood inflammatory/immune markers with outcomes in (neo)adjuvant breast cancer: a large single institutional study 

Abstract Disclosures

Abstract
Introduction: Peripheral blood markers have been reported to predict outcomes not only in cancer, but other conditions such as stroke, cardiac events, and even SARS-COV. A recent meta-analysis showed the predictive value of neutrophil-to-lymphocyte ratio (NLR) in breast cancer, but series are generally small. In this study, we will investigate the predictive value of peripheral blood inflammatory and immune markers on outcomes in stage I-III breast cancer patients who received either neo-adjuvant chemotherapy (NAC) or upfront surgery. Methods: Data on patients with stage I–III breast cancer treated from 2011–2017 were extracted from a prospectively maintained Joint Breast Cancer Registry and merged with full blood count (FBC) results from a clinical management software. FBC was performed within one-month pre-chemo for NAC patients, and one-month pre-surgery for upfront surgery patients. In neoadjuvant patients, the endpoints are pathologic complete response (pCR) rate, overall survival (OS), and breast cancer-specific survival (BCSS). In adjuvant patients, the endpoints are BCSS and OS.

Joint Breast Cancer Registry Singapore